<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8639" href="/d/html/8639.html" rel="external">see "Black widow spider (Latrodectus mactans) antivenom: Drug information"</a> and <a class="drug drug_patient" data-topicid="11555" href="/d/html/11555.html" rel="external">see "Black widow spider (Latrodectus mactans) antivenom: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1045279"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antivenin</span></li></ul></div>
<div class="block dop drugH1Div" id="F136046"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="07bfec59-9a7a-42b4-ae56-3b8bf42e0502">Envenomation due to <i>Latrodectus mactans</i>; envenomation due to other <i>Latrodectus</i> spp</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Envenomation due to <i>Latrodectus mactans</i>; envenomation due to other <i>Latrodectus</i> spp:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Limited data in infants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25275351','lexi-content-ref-22116992','lexi-content-ref-22175789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25275351','lexi-content-ref-22116992','lexi-content-ref-22175789'])">Ref</a></span>): Limited data available for some types of envenomations.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites; a case report describes use of antivenin administration up to 90 hours after bite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10049091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10049091'])">Ref</a></span>); however, delayed administration may decrease effectiveness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19274505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19274505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Controlled clinical studies for effectiveness and safety in pediatric patients have not been conducted. Antivenin has reportedly been used successfully in a 2-year-old pediatric patient who experienced black widow spider envenomation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25275351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25275351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">If with sensitivity testing a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with IV diphenhydramine and an H<sub>2 </sub>blocker while having a syringe of epinephrine at the bedside.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;12 years: IM; IV (preferred): One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IM, IV: One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064894"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51064895"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F136038"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8639" href="/d/html/8639.html" rel="external">see "Black widow spider (Latrodectus mactans) antivenom: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f766b093-c1e6-4a85-8d4d-4ba3bce8088a">Envenomation due to <i>Latrodectus</i>
<i>mactans</i> (black widow spider); envenomation due to other <i>Latrodectus</i> spp.</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Note:</b> The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites (case report of antivenin administration up to 90 hours after bite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10049091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10049091'])">Ref</a></span>)). However, delayed administration may decrease effectiveness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19274505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19274505'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Envenomation due to</b>
<b>
<i>Latrodectus mactans</i></b>
<b> (black widow spider); envenomation due to other</b>
<b>
<i>Latrodectus</i></b>
<b> spp. (off-label use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11407497','lexi-content-ref-12807312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11407497','lexi-content-ref-12807312'])">Ref</a></span>):</b> If sensitivity testing is performed, a positive reaction to a skin or conjunctival test occurs, and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H<sub>2</sub>-blocker while having a syringe of epinephrine at the bedside: <b>IM, IV:</b> One vial (2.5 mL); a second dose may be needed in some cases; more than 1 to 2 vials are rarely required for rapid resolution of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11407497','lexi-content-ref-33432350','lexi-content-ref-32179049','lexi-content-ref-22058673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11407497','lexi-content-ref-33432350','lexi-content-ref-32179049','lexi-content-ref-22058673'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990298"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50987600"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. </p></div>
<div class="block adr drugH1Div" id="F136020"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash (rare; associated with hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, serum sickness</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Muscle cramps</p></div>
<div class="block war drugH1Div" id="F136018"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergic reactions: May be less frequent than described in initial studies (Clark 2001; Nordt 2012; Offerman 2011). One retrospective study reviewed 163 cases of black widow spider envenomation; 58 patients received antivenin therapy and only 1 case of anaphylaxis occurred (Clark 1992). The risk of reaction appears to be greatest with bolus administration of undiluted antivenin (Clark 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed serum sickness: Delayed serum sickness, albeit uncommon, may occur 1 to 2 weeks following administration, especially when large doses are used (Clark 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">• Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase the risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria; fatal anaphylaxis has been reported in patients with a history of asthma. All patients require close monitoring in a setting where resuscitation can be performed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elderly patients: Due to an increased risk for complications of envenomation, the administration of antivenin may be the preferred initial therapy in patients &gt;60 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Thimerosal: Some products may contain thimerosal.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Desensitization: A desensitization protocol is available from the manufacturer if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration (Rojnuckarin 2009); the risk of allergic reaction may be less frequent than described in initial studies (Clark 2001; Nordt 2012; Offerman 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin/conjunctival test: A skin or conjunctival test may be performed prior to use and a sensitivity testing protocol is provided by the manufacturer; however, the utility of skin and conjunctival tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (WHO 2005). Normal horse serum (1:10 dilution) is included for sensitivity testing. The absence of a skin or conjunctival hypersensitivity reaction does not exclude the possibility of anaphylaxis or hypersensitivity following antivenin administration. The false-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient. Sensitivity testing for antivenom reactions is frequently unreliable with false-positive and false-negative results (Klaewsongkram 2009).</p></div>
<div class="block foc drugH1Div" id="F24673690"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6000 Antivenin units</p></div>
<div class="block geq drugH1Div" id="F136014"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block admp drugH1Div" id="F52612251"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer antivenin into the anterolateral thigh. Apply tourniquet proximal to the injection site if an adverse reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse antivenin over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11407497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11407497'])">Ref</a></span>). IV administration preferred in severe cases, with shock, or in children &lt;12 years of age. There appears to be no clinical difference in efficacy between the IM and IV route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18400776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18400776'])">Ref</a></span>). If an immediate hypersensitivity reaction occurs, immediately interrupt antivenin infusion and provide appropriate supportive therapy. If administration of antivenin can be resumed after control of the reaction, reinitiate at a slower infusion rate.</p></div>
<div class="block adm drugH1Div" id="F136029"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer antivenin in the anterolateral thigh; apply a tourniquet proximal to the injection site if an adverse systemic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer antivenin over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11407497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11407497'])">Ref</a></span>); IV administration is preferred in severe cases, with shock. There appears to be no clinical difference in efficacy between the IM and IV route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18400776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18400776'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F136035"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes: </i>Guidelines suggest that at least 1 vial be stocked in areas with indigenous black widow spiders. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53565476"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of patients with symptoms (eg, cramping, intractable pain, and hypertension that are unresponsive to other therapies [eg, benzodiazepines, opioids]) due to <i>Latrodectus mactans</i> (black widow spider) envenomation (FDA approved in children and adults); latrodectism due to other<i> Latrodectus</i> species found in North America (eg, <i>L. bishopi</i>, <i>L. geometricus</i>, <i>L. hesperus</i>, <i>L. variolus</i>) may be treated with antivenin intended for use in patients envenomed by <i>Latrodectus mactans</i>.</p></div>
<div class="block cyt drugH1Div" id="F13298765"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218053"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F136033"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Russell, 1979; Sherman, 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Treatment of a pregnant patient with antivenom should be considered early in the course of an envenomation and in patients experiencing local, regional, or systemic effects refractory to opioids and/or benzodiazepines (Brown, 2013).</p></div>
<div class="block mopp drugH1Div" id="F53565459"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs; hypersensitivity reactions; serum sickness (for 2 to 3 weeks following administration); worsening of symptoms due to envenomation.</p></div>
<div class="block pha drugH1Div" id="F136017"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Neutralizes the venom of <i>Latrodectus mactans</i> (black widow spiders), but may also be effective following envenomation by other <i>Latrodectus</i> species (including <i>L. bishopi, L. geometricus, L. hesperus,</i> and <i>L. variolus</i>) (Clark 2001; Isbister 2003).</p></div>
<div class="block phk drugH1Div" id="F10180464"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Onset of action: Within 30 minutes; symptoms of envenomation usually subside after 1 to 3 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58186806"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aracmyn plus</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aracmyn plus</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Antivenin (<i>Latrodectus mactans</i>) (black widow spider antivenin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298218">
<a name="23298218"></a>Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed" id="23298218" target="_blank">23298218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11407497">
<a name="11407497"></a>Clark RF. The Safety and Efficacy of Antivenin <i>Latrodectus mactans</i>. <i>J Toxicol Clin Toxicol</i>. 2001;39(2):125-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/11407497/pubmed" id="11407497" target="_blank">11407497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1351707">
<a name="1351707"></a>Clark RF, Wethern-Kestner S, Vance MV, et al. Clinical Presentation and Treatment of Black Widow Spider Envenomation: A Review of 163 Cases. <i>Ann Emerg Med</i>. 1992;21(7):782-787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/1351707/pubmed" id="1351707" target="_blank">1351707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33432350">
<a name="33432350"></a>Currin-Sills G, Wilson SM, Benett R. A review of black widow (Araneae: Theridiidae) envenomation, epidemiology, and antivenom utilization in Canada. <i>J Med Entomol.</i> 2021;58(1):99-103. doi:10.1093/jme/tjaa148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/33432350/pubmed" id="33432350" target="_blank">33432350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23380292">
<a name="23380292"></a>Dart RC, Bogdan G, Heard K, et al. A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom.<i> Ann Emerg Med</i>. 2013;61(4):458-467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/23380292/pubmed" id="23380292" target="_blank">23380292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15306718">
<a name="15306718"></a>Diaz JH. The Global Epidemiology, Syndromic Classification, Management, and Prevention of Spider Bites. <i>Am J Trop Med Hyg</i>. 2004;71(2):239-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/15306718/pubmed" id="15306718" target="_blank">15306718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32179049">
<a name="32179049"></a>Di Paola G, Cirronis M, Scaravaggi G, et al. Latrodectism in Italy: first report of successful treatment of <i>L. tredecimguttatus</i> envenomation using <i>L. mactans</i> antivenom from North America. <i>Toxicon</i>. 2020;179:107-110. doi:10.1016/j.toxicon.2020.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/32179049/pubmed" id="32179049" target="_blank">32179049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19274505">
<a name="19274505"></a>Edberg AL, Lanphear JR, Riley BD, et al. Toxic Traveler? Latrodectus Species Envenomation in Michigan With Refractory Symptoms After Antivenin Administration. <i>Clin Toxicol (Phila)</i>. 2009;47(4):356-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/19274505/pubmed" id="19274505" target="_blank">19274505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;12218(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25275351">
<a name="25275351"></a>Goel SC, Yabrodi M, Fortenberry J. Recognition and successful treatment of priapism and suspected black widow spider bite with antivenin. <i>Pediatr Emerg Care</i>. 2014;30(10):723-724. doi:10.1097/PEC.0000000000000235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/25275351/pubmed" id="25275351" target="_blank">25275351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8191768">
<a name="8191768"></a>Handel CC, Izquierdo LA, Curet LB. Black Widow Spider (<i>Latrodectus mactans</i>) Bite During Pregnancy. <i>West J Med</i>. 1994;160(3):261-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/8191768/pubmed" id="8191768" target="_blank">8191768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21641165">
<a name="21641165"></a>Hoyte CO, Cushing TA, Heard KJ. Anaphylaxis to black widow spider antivenom. <i>Am J Emerg Med</i>. 2012;30(5):836.e1-e2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/21641165/pubmed" id="21641165" target="_blank">21641165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21762981">
<a name="21762981"></a>Isbister GK, Fan HW. Spider Bite. <i>Lancet</i>. 2011;378(9808):2039-2047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/21762981/pubmed" id="21762981" target="_blank">21762981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18400776">
<a name="18400776"></a>Isbister GK, Brown SG, Miller M, et al. A Randomised Controlled Trial of Intramuscular vs Intravenous Antivenom for latrodectism-the RAVE Study. <i>QJM</i>. 2008;101(7):557-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/18400776/pubmed" id="18400776" target="_blank">18400776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12807312">
<a name="12807312"></a>Ibister GK, Graudins A, White J, Warrell D. Antivenom treatment in arachnidism. <i>J Toxicol Clin Toxicol</i>. 2003;41(3):291-300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/12807312/pubmed" id="12807312" target="_blank">12807312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18929526">
<a name="18929526"></a>Klaewsongkram J. A role of snake antivenom skin test from the allergist's point of view. <i>Acta Trop</i>. 2009;109(1):84-85; author reply 86. doi:10.1016/j.actatropica.2008.09.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/18929526/pubmed" id="18929526" target="_blank">18929526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21293781">
<a name="21293781"></a>Levine M, Canning J, Chase R, et al. Cardiomyopathy Following <i>Latrodectus</i> Envenomation. <i>West J Emerg Med</i>. 2010;11(5):521-523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/21293781/pubmed" id="21293781" target="_blank">21293781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22116992">
<a name="22116992"></a>Monte AA, Bucher-Bartelson B, Heard KJ. A US Perspective of Symptomatic <i>Latrodectus spp.</i> Envenomation and Treatment: A National Poison Data System Review. <i>Ann Pharmacother</i>. 2011;45(12):1491-1498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/22116992/pubmed" id="22116992" target="_blank">22116992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22175789">
<a name="22175789"></a>Nordt SP, Clark RF, Lee A, et al. Examination of Adverse Events Following Black Widow Antivenom Use in California. <i>Clin Toxicol (Phila)</i>. 2012;50(1):70-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/22175789/pubmed" id="22175789" target="_blank">22175789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058673">
<a name="22058673"></a>Offerman SR, Daubert GP, Clark RF. The Treatment of Black Widow Spider Envenomation With Antivenin <i>Latrodectus Mactans</i>: A Case Series. <i>Permanente J</i>. 2011;15(3):76-81. doi:10.7812/TPP/10-136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/22058673/pubmed" id="22058673" target="_blank">22058673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10049091">
<a name="10049091"></a>O'Malley GF, Dart RC, Kuffner EF. Successful Treatment of Latrodectism With Antivenin After 90 hours. <i>N Engl J Med</i>. 1999;340(8):657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/10049091/pubmed" id="10049091" target="_blank">10049091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rojnuckarin.1">
<a name="Rojnuckarin.1"></a>Rojnuckarin P. Antivenom Skin Test: Theory Versus Practice. <i>Acta Tropica</i>. 2009;109(1):86.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-442109">
<a name="442109"></a>Russell FE, Marcus P, Streng JA. Black Widow Spider Envenomation During Pregnancy: Report of a Case. <i>Toxicon</i>. 1979;17(2):188-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/442109/pubmed" id="442109" target="_blank">442109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15163574">
<a name="15163574"></a>Saucier JR. Arachnid Envenomation. <i>Emerg Med Clin North Am</i>. 2004;22(2):405-422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/15163574/pubmed" id="15163574" target="_blank">15163574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25978056">
<a name="25978056"></a>Shackleford R, Veillon D, Maxwell N, et al. The black widow spider bite: differential diagnosis, clinical manifestations, and treatment options. <i>J La State Med Soc</i>. 2015;167(2):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/25978056/pubmed" id="25978056" target="_blank">25978056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11024247">
<a name="11024247"></a>Sherman RP, Groll JM, Gonzalez DI, et al. Black Widow Spider (<i>Latrodectus mactans</i>) Envenomation in a Term Pregnancy. <i>Curr Surg</i>. 2000;57(4):346-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/black-widow-spider-latrodectus-mactans-antivenom-pediatric-drug-information/abstract-text/11024247/pubmed" id="11024247" target="_blank">11024247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization. Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region. 2005. Geneva. http://www.medbox.org/preview/52724466-84a0-4100-ae90-15f51fcc7b89/doc.pdf
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 12889 Version 126.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
